Antitumor activity of novel purine acyclic nucleotide analogs PMEA and PMEDAP

In Vivo

Volumn 11, Issue 2, 1997, Pages 163-167

  Otová, Berta ^a   Zídek, Zdeněk ^b   Holý, Antonín ^c   Votruba, Ivan ^c   Sladká, Milada ^a   Marinov, Iuri ^d   Lešková, Veronika ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF MATHEMATICS   (Czech Republic)

^c INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^d INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Acyclic nucleotides; Antitumor activity; In vitro cytotoxicity; Rat T cell lymphomas; T cell modulation

Indexed keywords

2,6 DIAMINOPURINE DERIVATIVE; ADEFOVIR; ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; LYMPHOMA; LYMPHOMA CELL LINE; MITOSIS INHIBITION; NONHUMAN; RAT; SPLEEN CELL; T LYMPHOCYTE;

EID: 0031006322     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Jones RJ, Bischofberger N: Minireview: Nucleotide prodrugs. Antivir Res 27: 1-17, 1995.
2. Clercq E, Holy A, Rosenberg I, Sakuma T, Baizarini J, and Maudgal PC: A novel selective broad-spectrum anti-DNA virus agent. Nature 25: 464-467, 1986.
3. Holy A, Votruba I, Merta A, Cermy J, Vesely J, Vlach J, Sediva K, Rosenberg I, Otmar M Hrebabecky H, Travnicek M, Vonka V, Snoeck R, and De Clercq E: Acyclic nucleotide analogs: synthesis, antiviral activity and inhibition effects on some cellular and virus-encoded enzymes in vitro. Antiviral Res 13: 295-312, 1990.
4. Holy A: Isopolar Phosphorus-Modified Nucleotide Analogues In: De Clercq E(ed): Advances in Antiviral Drug Design. vol 1 JAI Press, Inc, Greenwich, CT (USA), pp 179-232, 1994.
5. Balzarini J, Naesens L, Herdewijn P, Rosenberg I, Holy A, Powels R, Baba M, Johns DG, and De Clercq E: Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci USA 86: 332-336, 1989.
6. Pauwels R, Balzarini J, Schols D, Baba M, Desmyter J, Rosenberg I, Holy A and De Clercq E: Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob. Agents Chemother 32: 1025-1030, 1988.
7. Gangemi JD, Cozens RM, De Clercq E, Balzarini J, and Hochkeppel HK: 9-(2-Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections. Antimicrob Agents Chemother 33: 1864-1868, 1989.
8. Naesens L, Balzarini J, Rosenberg I, Holy A, and De Clercq E: 9-(2-Phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP): A novel agent with anti-human immunodeficiency virus activity in vitro and potent anti-Moloney murine sarcoma virus activity in vivo. Eur J Clin Microbiol Infect Dis 8: 1043-1047, 1989.
9. Yokota T, Konno K, Shigeta S, Holy A, Balzarini J and De Clercq E: Inhibitory Effects of Acyclic Nucleoside Phosphonate Analogues on Hepatitis B Virus DNA Synthesis in Hb611 Cells. Antivir Chem. Chemother 5: 57-63, 1994.
10. Cundy KC, BarditchCrovo PA, Walker RE, Collier AC, Ebeling D, Toole J, and Jafee HS: Clinical Pharmacokinetics of Adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother 39: 2401-2405, 1995
11. Arends S, Vanhalteren E, Kamp W, and Schokker J: Safety of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in patients with human immunodeficiency virus infection - A pilot study. Pharm World Sci 18: 30-34, 1996
12. Otová B, Krenova D, Zidek Z, Holy A, Votruba I and Kren V: Cytostatic effect of 9-(2-phosphonomethoxyethyl)adenine (PMEA). III. Rat and mouse carcinomas and sarcomas. Folia Biol. (Praha) 39: 311-314, 1994.
13. Vesely J, Merta A, Votruba I, Holy A and Rosenberg I: Ihe cytostatic effects and mechanism of action of antiviral acyclic nucleotide analogues in L1210 mouse leukemic cells. Neoplasma 37: 105-110, 1990.
14. Otová B, Sladka M, Votruba I, Holy A and Kren V: Cytostatic effect of 9-(2-phosphonomethoxyethyl)adenine (PMEA). I. Lymphatic leukemia KPH-Lw-I in Lewis rats. Folia Biol (Praha) 39: 142-152, 1993.
15. Otová B, Sladka M, Blazek K, Schramlova J, Votruba I and Holy A: Cytostatic effect of 9-(2-phosphonomethoxyethyl)adenine (PMEA). II. Lymphoblastic leukemia in Sprague-Dawley rats. Folia Biol (Praha) 39: 142-149, 1993.
16. Otova B, Sladka M, Panczak A and Marinov I: Biological characteristics of spontaneous transplantable T-cell lymphomas in inbred Sprague-Dawley rat. Transplant. Proc. in press, 1997.
17. Holy A, Rosenberg I, Dvorakova H: Synthesis of N-(2-phosphonylmethoxyethyl) derivatives of heterocyclic bases. Collect. Czech. Chem. Commun 54: 2190-2210, 1989.
18. Rojas E, Herrera LA, Sordo M, Gonsebatt ME, Montero R, Rodriguez R and Ostrosky-Wegman P: Mitotic index and cell proliferation kinetics for identification of antineoplastic activity. Anti-Cancer Drugs 4: 637-640, 1993.
19. Bellamy WT, Dalton WS and Dorr RT: The cinical relevance of multidrug resistance. Cancer Invest. 8: 545-560, 1990.
20. Holzman D: Apoptosis provides new targets for chemotherapy. J Nat Cancer Inst 88: 1098-1100, 1996.
21. Kramata P, Votruba I, Otova B and Holy A: Different inhibitory properties of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases α, δ, and ε Molecular Pharmacol 49: 1005-1011, 1996.
22. Rose WC, Crosswell AE, Bronson JJ, and Martin JC: In vivo antitumor activity of 9-[(2-phosphonylmethoxy)ethyl]guanine and related phosphonate nucleotide analogues. J Natl Cancer Inst 82: 510-512, 1990.
23. Kren V, Otova B, Elleder D, Elleder M, Panczak A and Sladka M: Model of acute graf-vs-host-disease in adult (SHR x BN.lx)FI rats and its inhibition by adenine analog. Transpl Proc 25: 2822-2823, 1993.
24. Otova B, Zidek Z, Holy A, Votruba I, Frankova D: Immunomodulatory properties of 9-(2-phosphono-methoxyethyl)adenine (PMEA). Folia Biol Prague 40: 185-192, 1994.
25. Villani N, Calio R, Balestra E, Bȧlzarini J, De Clercq E, Fabrizi E, Pemo CF, and Del Gobo V: 9-(2-phosphonylmethoxyethyl)adenine increases the survival of influenza virus-infected mice by an enhancement of the immune system. Antiviral Res 25: 81-89, 1994.
26. Kunder SC, Black PL, Hall BE, and Ussery MA: PMEA has immunomodulatory activity and inhibits reverse transcriptase in the Rauscher murine leukemia virus (RMuLV) model. Antiviral Res 26: A276, 1995.